This model allowed us to primarily study the effect of Prl2 deletion on Tp53-null thymic lymphomas, which accumulate hallmark mutations observed in T-cell acute lymphoblastic leukemia in humans (21). The gene discussed is TP53; the disease is thymus lymphoma.